A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis.

ABSTRACT:

Background

Tobacco smoking is associated with a reduced risk of developing sarcoidosis, and we previously reported that nicotine normalizes immune responses to environmental antigens in patients with active pulmonary sarcoidosis. The effects of nicotine on the progression of pulmonary sarcoidosis are unknown.

Research question

Is nicotine treatment well tolerated, and will it improve lung function in patients with active pulmonary sarcoidosis?

Study design and methods

With local institutional review board approval, a randomized, double-blind, controlled pilot trial was conducted of daily nicotine transdermal patch treatment (21 mg daily) or placebo patch use for 24 weeks. The Ohio State University Wexner Medical Center and Cleveland Clinic enrolled 50 consecutive subj

SUBMITTER: Crouser ED 

PROVIDER: S-EPMC8546242 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature